# Dynasil Corporation of America Announces Results of Tender Offer - Dynasil Corporation
Canonical URL: https://biopharmsignal.com/news/DYSL/dynasil-corporation-of-america-announces-results-of-tender-offer-dynasil-corpora-9e5649f0
Ticker: DYSL
Company: Dynasil
Source: Dynasil
Published: 2026-07-09 00:01 EST
Original Source URL: https://www.dynasil.com/about/news/
## Summary

Concord, Mass., December 1, 2022 – Dynasil Corporation of America (“Dynasil” or the “Company”), today announced the results of its tender offer to purchase up to 8,000,000 shares of the Company’s common stock a...

## Article Body
Concord, Mass., December 1, 2022 – Dynasil Corporation of America (“Dynasil” or the “Company”), today announced the results of its tender offer to purchase up to 8,000,000 shares of the Company’s common stock at a purchase price of $2.49 per share, in cash, less any applicable withholding taxes and without interest, representing an aggregate purchase price of $19.9 million. The tender offer expired at one minute following 11:59 p.m. (Eastern Time) on November 30, 2022.

Based on the final count by the depositary for the tender offer, 6,992,844 shares of common stock were validly tendered and not validly withdrawn, which the Company will purchase for a total cost of approximately $17.4 million excluding fees and expenses relating to the tender offer. The shares accepted for purchase in the tender offer represent approximately 47% of Dynasil’ s issued and outstanding shares of common stock.

Stockholders who tendered their shares should receive payment through either the depository or their brokerage over the next couple of weeks.

Alliance Advisors, LLC served as information agent for the tender offer. Continental Stock Transfer & Trust Company served as the depositary for the tender offer. Stockholders who have questions or would like additional information about the tender offer may contact the information agent for the tender offer, Alliance Advisors, LLC at 877-728-5022.

About Dynasil

Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil Corporation of America is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive portfolio of issued and pending U.S. patents. The Company is based in Concord, MA, with additional operations in MA, NJ, and the United Kingdom. More information about the Company is available at www.dynasil.com .
## Recent Company News
- 2026-07-09 00:01 EST — [Dynasil Appoints Nirmal Parikh, VP of Marketing - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-appoints-nirmal-parikh-vp-of-marketing-dynasil-corporation-261ff65b) — Source: Dynasil
- 2026-07-09 00:01 EST — [Dynasil Corporation of America Announces Results of Tender Offer - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-corporation-of-america-announces-results-of-tender-offer-dynasil-corpora-9e5649f0) — Source: Dynasil
- 2026-07-09 00:01 EST — [Dr. Matthew Dallimore Appointed President of Dynasil - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dr-matthew-dallimore-appointed-president-of-dynasil-dynasil-corporation-61b6cb48) — Source: Dynasil
- 2021-01-07 15:35 EST — [Dynasil Appoints Militram Futuristic Technologies to Target Israel’s Fast Growing Industrial, Commercial and Military Segments - Dynasil Corporation](https://biopharmsignal.com/news/DYSL/dynasil-appoints-militram-futuristic-technologies-to-target-israel-s-fast-growin-63a4781e) — Source: Dynasil
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)